Copper Complex Halts Botulinum Neurotoxin Poisoning
|
By HospiMedica International staff writers Posted on 12 Jun 2017 |
A new study describes how a readily available metal salt could provide a new therapy for Botulinum Neurotoxin type A (BoNT/A), the most common and deadly cause of human botulism.
Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.
They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.
“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”
BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.
Related Links:
Scripps Research Institute
Boston University
Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.
They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.
“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”
BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.
Related Links:
Scripps Research Institute
Boston University
Latest Critical Care News
- Ultrasound Controlled Artificial Muscles Pave Way for Soft Robots
- AI-Powered Alerts Reduce Kidney Complications After Heart Surgery
- Algorithm Predicts and Lengthens Pacemaker Battery Life
- Novel Pill Could Mimic Health Benefits of Bariatric Surgery
- AI Models Identify Patient Groups at Risk of Being Mistreated in Hospital ED
- CPR Guidelines Updated for Pediatric and Neonatal Emergency Care and Resuscitation
- Ingestible Capsule Monitors Intestinal Inflammation
- Wireless Implantable Sensor Enables Continuous Endoleak Monitoring
- Pulse Oximeter Index Offers Non-Invasive Guides for Fluid Therapy
- Wearable Patch for Early Skin Cancer Detection to Reduce Unnecessary Biopsies
- 'Universal' Kidney to Match Any Blood Type
- Light-Based Technology to Measure Brain Blood Flow Could Diagnose Stroke and TBI
- AI Heart Attack Risk Assessment Tool Outperforms Existing Methods
- Smartphone Imaging System Enables Early Oral Cancer Detection
- Swallowable Pill-Sized Bioprinter Treats GI Tract Injuries

- Personalized Brain “Pacemakers” Could Help Patients with Hard-To-Treat Epilepsy
Channels
Surgical Techniques
view channel
'Lab-on-a-Scalpel' Provides Real-Time Surgical Insights for POC Diagnostics in OR
During surgery, waiting for laboratory test results can slow critical decision-making, especially in emergency or oncological procedures. Now, researchers have introduced a new diagnostic concept: a surgical... Read more
Biodegradable Brain Implant Prevents Glioblastoma Recurrence
Preventing glioblastoma from returning after surgery remains one of the greatest challenges in neuro-oncology. Even after tumor removal and radiochemotherapy, this aggressive brain cancer almost always... Read more
Tiny 3D Printer Reconstructs Tissues During Vocal Cord Surgery
Stiff vocal folds are a common complication after vocal cord surgery, affecting how patients speak and recover. Hydrogels can help reduce this risk by supporting tissue healing, but delivering them precisely... Read more
Minimally Invasive Procedure for Aortic Valve Disease Has Similar Outcomes as Surgery
Diagnosing and deciding how best to treat severe aortic valve stenosis is a critical challenge, especially as the number of affected patients grows with age. Clinicians have long relied on open-heart surgery... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read moreFirst-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies
Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
B. Braun Acquires Digital Microsurgery Company True Digital Surgery
The high-end microsurgery market in neurosurgery, spine, and ENT is undergoing a significant transformation. Traditional analog microscopes are giving way to digital exoscopes, which provide improved visualization,... Read more
CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is scheduled to be held from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou.... Read more







